Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final

MLA

“Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final.” Fair Disclosure Wire, Mar. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.195808393&authtype=sso&custid=ns315887.

APA

Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final. (2009). Fair Disclosure Wire.

Chicago

“Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final.” 2009. Fair Disclosure Wire, March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.195808393&authtype=sso&custid=ns315887.